This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Telik Fails Ethics Test

There were no apologies, no statements of regret from Telik (TELK) management on Wednesday night's quarterly conference call.

That's not necessarily surprising, but it is disappointing. After all, Telik CEO Michael Wick and Chief Medical Officer Gail Brown (who's also Wick's wife) are involved in one of the most serious ethical breaches of clinical trial research that I've ever come across in biotech.

In June, Telik disclosed the results of two phase III clinical trials in which patients given the company's experimental cancer drug Telcyta actually died faster than similar patients in the studies' control arms.

Telcyta was supposed to benefit these cancer patients; instead, desperate cancer patients died quicker than they should have.

Wick, Brown and the rest of Telik's management team knew the disastrous results of the Telcyta clinical trials back in December 2006 -- five months before it was disclosed publicly -- yet they made the decision to keep the information secret.

Telik didn't warn patients in other ongoing Telcyta studies, the company didn't tell the U.S. Food and Drug Administration about the deaths; it didn't tell investors or anyone else outside the company.

The FDA has put a hold on further Telcyta clinical trials and the agency is investigating Telik over its failure to disclose the patient deaths to the agency in a timely manner.

With all this hanging over the heads of Wick and Brown, you'd think they'd say something on Wednesday night's conference call -- the first time since June that Telik management has spoken publicly.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
TELK $2.75 -8.33%
AAPL $132.02 1.90%
FB $80.13 1.00%
GOOG $538.55 1.20%
TSLA $247.36 -0.04%

Markets

DOW 18,163.95 +122.41 0.68%
S&P 500 2,121.14 +16.94 0.81%
NASDAQ 5,090.8830 +58.1320 1.16%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs